Sartorius : Conference Call FY|2020 Presentation

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.

This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

2

Highlights

•  Strong finish to the year in both Group divisions

•  2020 preliminary figures show double digit growth across the board

•  Bioprocess Solutions Division: Continued high underlying demand; plays a key role as a provider for vaccine technologies

•  Lab Products & Services Division: First half significantly impacted by the pandemic; progressive rebound since Q3

•  Successful closing of strategically important acquisitions, one more recently announced

•  Outlook for 2021: Significant sales revenue growth projected on all levels

•  2025 targets updated and raised